Home > Publications database > Response improvement rather than response status after 1st ASCT is a significant prognostic factor for survival benefit from tandem compared to single ASCT in multiple myeloma patients. |
Journal Article | DKFZ-2020-00697 |
; ; ; ;
2020
Elsevier Health Sciences
[S.l.]
This record in other databases:
Please use a persistent id in citations: doi:10.1016/j.bbmt.2020.03.006
Abstract: High-dose chemotherapy and autologous stem cell transplantation (ASCT) have been an effective treatment for newly diagnosed multiple myeloma patients for over three decades. However, it remains unclear which patients benefit from tandem compared to single ASCT. Here, we retrospectively analyzed 978 trial and non-trial patients who underwent single or tandem ASCT in Heidelberg or other German Speaking Myeloma Multicenter Group centers. Our results show that response improvement after 1st ASCT is a significant prognostic factor for progression-free survival benefit from tandem versus single ASCT (multivariable analysis p = 0.002, HR = 0.64, 95 % CI [0.48, 0.85], interaction p = 0.02). Depth of response after 1st ASCT and cytogenetic profile did not have a significant prognostic effect on survival benefit from tandem ASCT. In conclusion, our results suggest that not the response depth but rather response improvement after 1st ASCT is of prognostic significance regarding the benefit of tandem versus single ASCT.
![]() |
The record appears in these collections: |